Severity
Moderate
FDA Drug recall · Reported April 24, 2019
Subpotent Product: assay results for Amoxicillin were below the specification limits.
Teva Pharmaceuticals USA recalled Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in (a) 150 mL bottle (NDC … - a moderate-severity action.
Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in (a) 150 mL bottle (NDC … was recalled by Teva Pharmaceuticals USA in April 24, 2019. Reason: Subpotent Product: assay results for Amoxicillin were below the specification limits.. Check the official notice for the remedy. Verify recall #D-1205-2019 with the FDA Drug before acting.
The recall
Teva Pharmaceuticals USA issued this moderate-severity FDA Drug recall-Subpotent Product: assay results for Amoxicillin were below the specification limits..
Sourced from official FDA Drug enforcement records. Verify recall #D-1205-2019 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1205-2019) was formally reported on April 24, 2019, with the manufacturer initiating the action on April 12, 2019. It is classified under Moderate severity (Class II), with a current status of Terminated. Teva Pharmaceuticals USA is listed as the recalling firm, operating out of North Wales, PA. Federal records list the affected scope as 171,488 150 mL and 80 mL bottles.
The documented reason for this recall is: Subpotent Product: assay results for Amoxicillin were below the specification limits. Distribution data in the federal record shows the product reached: Nationwide in the USA and Puerto Rico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 3,731 children & baby products recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
171,488 150 mL and 80 mL bottles
Related Recalls
6
0 from same agency
Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in (a) 150 mL bottle (NDC 0093-4150-80) (b) 80 mL bottle (NDC 0093-4150-79), Rx Only, Manufactured in Canada By: Teva Canada Limited Toronto, Canada, M1B2K9, Manufactured For: Teva Pharmaceuticals USA, INC. North Wales, PA 19454.
Subpotent Product: assay results for Amoxicillin were below the specification limits.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-1205-2019 |
| Date reported | April 24, 2019 |
| Date initiated | April 12, 2019 |
| Recalling firm | Teva Pharmaceuticals USA |
| Firm location | North Wales, PA |
| Affected scope | 171,488 150 mL and 80 mL bottles |
| Distribution | Nationwide in the USA and Puerto Rico |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Xishentang Dongguan Trading Co, Ltd., dba Pretty-Life, of China · 2026-07-02
Diamond Wipes International, Inc. of Chino, California · 2026-07-02
· 2026-07-02
· 2026-07-02
Sanven Technology Ltd., dba Vevor, of Rancho Cucamonga, California · 2026-07-02
Compare this recall with AMASKY Nursing Pillows Recalled Due to Risk of Serious Inju… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported April 24, 2019. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.